Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Continue Reading![](https://s0.storage.snapzu.com/favicons/c/n/b/c/www.cnbc.com.png)
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Continue Reading
Join the Discussion